Curcumin C3 Reduct®

Curcumin C3 Reduct®, from Curcuma longa, is the first EFSA-approved Tetrahydrocurcuminoids (THCs) in Europe, addressing bioavailability with its innovative formulation. Offering colorlessness, pH stability, and notable health benefits like organ protection and anti-inflammatory effects. This, new dispersible ingredient is perfectly suited for beverages and Sports Nutrition Market. "THE FIRST AND ONLY EFSA EVALUATED CURCUMIN PRODUCT" Sabinsa's C3 Reduct is the only EFSA-approved reductive metabolites of curcuminoids on the market. This means that formulators can take advantage of the huge functional benefits of this unique product, safe in the knowledge that it meets and surpasses the most stringent regulatory thresholds. C3 Reduct delivers effective, targeted antioxidant and anti-inflammatory functionalities, helping product formulators to appeal to consumers looking for effective, science-backed products. 140 mg daily 2 clinical studies 27 publications 95% tetrahydrocurcuminoids www.c3reduct.eu